MultiCell Announces 2004 Shareholders Meeting
Thursday May 6, 8:30 am ET
biz.yahoo.com
WARWICK, R.I.--(BUSINESS WIRE)--May 6, 2004--MultiCell Technologies, Inc. (OTCBB:EXTI - News) announced today that it will hold its 2004 Annual Stockholders Meeting in San Diego, CA on Wednesday, June 16, 2004.
The meeting is scheduled for 1:00 p.m. at the Holiday Inn Mission Valley Stadium, 3805 Murphy Canyon Road. The 2004 annual report and proxy statement are to be mailed in the next ten days to shareholders of record as of April 26. The proxy contains three routine issues to be voted upon by shareholders; the election of four directors, the adoption of the 2004 Equity Incentive Plan and the ratification of J.H. Cohn, LLP as independent public accountants.
Jerry Newmin, Chairman, Chief Executive Officer and President, stated, "We have scheduled the meeting to coincide with the 7th International Conference on Drug-Drug Interactions being held by the Institute for Scientific Exchange in San Diego June 14-16. Dr. Andrew Parkinson, founder of the Company's licensee XenoTech, LLC, is a featured speaker at this conference and will present MultiCell's immortalized non-tumorigenic human hepatocytes to pharmaceutical attendees. Dr. Parkinson has also been invited to attend MultiCell's shareholders' meeting to bring our stockholders up to date on XenoTech's progress and accomplishments."
Dr. Ronald Faris, Chief Science Officer of MultiCell, added, "I will be conducting the first meeting of the newly-merged Company's restructured Scientific Advisory Board concurrently with the annual meeting. Management of the Company's intellectual property is our top priority. The Scientific Advisory Board will meet to discuss planned research and development programs, our intellectual property pipeline and general scientific oversight activities."
About MultiCell:
MultiCell Technologies, Inc., (OTCBB:EXTI - News) provides hepatic (liver) cells and cell lines to pharmaceutical companies for drug discovery, and is developing cell-based toxicological and drug screening tests and biologics for use in diagnostic and therapeutic applications. MultiCell's cellular product expertise also enables production of liver-derived therapeutic proteins. The Company's Xenogenics subsidiary is developing the Sybiol® synthetic bio-liver device. MultiCell's corporate and research headquarters are in Warwick, Rhode Island. For more information about MultiCell and its Xenogenics subsidiary, visit www.multicelltechnologies.com.
The matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially. These risks are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission including the Company's Annual Report, Quarterly Reports and other periodic filings. These forward-looking statements speak only as of the date hereof. The Company disclaims any intent or obligation to update these forward-looking statements.
--------------------------------------------------------------------------------
Contact:
MultiCell Technologies Inc.
Jerry Newmin, 401-384-6789
--------------------------------------------------------------------------------
Source: MultiCell Technologies Inc. |
